Caliway Biopharmaceuticals Co Ltd 6919

TWSE · Taiwan · Health Technology

TWD 79.10+0.10 (+0.13%)

Market closed· Oct 1, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Caliway Biopharmaceuticals Co Ltd 6919

TWSE · Taiwan · Health Technology

TWD 79.10+0.10 (+0.13%)

Market closed· Oct 1, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-16.65% · 6MFull-screen chart

Open TWD 79.40High TWD 80.70Low TWD 79.00Close TWD 79.10Volume 2.67M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 79.00
Day range: TWD 79.00 – TWD 80.70
52-week range: TWD 75.10 – TWD 195.00
Volume: 2.74M
Market cap: TWD 123.02B
Next earnings date: 2026-11-11
Avg. volume (1Y): 8.70M

Performance

1 week

-1.25%

1 month

-13.27%

3 months

-20.66%

6 months

-24.67%

Year to date

-48.47%

1 year

-58.37%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Taiwan
Exchange: TWSE
Shares outstanding: 1.56B
ISIN: TW0006919004
Beta: 0.85

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 23, 2026

Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction

Caliway Biopharmaceuticals (TWSE: 6919) on September 21 announced final statistical results from its randomized, single-blind, placebo-controlled Phase 2 clinical trial (CBL-0202DD) evaluating CBL-514 for the treatment of Dercum's Disease (DD), a rare and debilitating disorder characterized by painful lipomas. The study successfully achieved its primary efficacy endpoint, with CBL-514 demonstrating clinically meaningful and statistically significant pain reduction in both the Full Analysis Set (

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.